Stockwinners Market Radar for October 17, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:02 EDT Cadence Design expands collaboration with Samsung Foundry on 3D-IC design - Cadence Design Systems "announced that it has expanded its collaboration with Samsung Foundry to accelerate 3D-IC design. Using the Cadence platform, customers creating complex, next-generation hyperscale computing, mobile, automotive and AI applications can greatly optimize power, performance and area for each die. The PPA of a design can be impacted when chips are stacked in a 3D-IC configuration versus a 2D configuration due to the presence of large 3D structures like TSVs, which connect the stacked chips. In addition to blocking standard cell placement area, these structures block routing resources as well. The Cadence Integrity 3D-IC platform alleviates these traditional challenges, letting users create multiple TSV insertion scenarios and devise an optimal 3D structure placement on a die with reduced wirelength penalties while boosting PPA and productivity. The platform also lets users perform 3D-IC design planning, implementation and signoff from a single cockpit, making the design process faster and easier."

20:04 EDT Gogo completes construction of nationwide 5G network - The company states: "Gogo Business Aviation has finished construction of its nationwide Gogo 5G network. The 5G network now covers the contiguous United States and will expand into Canada beginning in 2023."

18:48 EDT Turquoise Hill reports Q3 copper production of 36.3K tons, down 13% y/y - The company reports: "Q3 Copper production of 36.3 thousand tonnes of copper in concentrate, a decrease of 13% y/y and an increase of 19% q/q. Q3 Gold production of 42.7 thousand ounces of gold in concentrate, a decrease of 67% y/y and a decrease of 10% q/q. Copper production guidance for 2022 remains within the range of 110,000 to 150,000 tonnes. Gold production guidance for 2022 has been revised from a range of 150,000 - 170,000 ounces to 165,000 - 185,000 ounces."

18:10 EDT Marathon Digital enters into settlement agreement with former CEO - The company states: "In connection with a dispute concerning the settlement of certain restricted stock unit awards previously granted to Merrick D. Okamoto, former CEO and Chairman of Marathon Digital Holdings, Inc., on October 12, 2022, the Company entered into a settlement agreement with Mr. Okamoto, pursuant to which the Company agreed to pay Mr. Okamoto $24 million. Mr. Okamoto agreed to a settlement and a broad release of known or unknown claims against the Company, which relate to the Company's Amended 2018 Equity Incentive Plan or related restricted stock unit award agreements. The Company entered into related settlement agreements in respect to certain restricted stock unit awards previously granted to five other individuals, including a director and our current Chief Executive Officer and Chairman, which total approximately $1 million in the aggregate."

17:38 EDT PWP files preliminay proxy statement to approve early liquidation - PWP Forward Acquisition Corp. I announced that it has filed a preliminary proxy statement to seek stockholder approval to adopt an amendment to its Amended and Restated Certificate of Incorporation to allow the Company to redeem all of its outstanding public shares and liquidate before December 31, 2022, in advance of the automatic termination date in its current Charter of March 12, 2023. Since PFAC's listing on NASDAQ on March 10, 2021, the Company's leadership has conducted a thorough search for the right target and evaluated a number of companies with the goal to complete an initial business combination that met its investment criteria. As a result, PFAC's leadership has determined that it is prudent and in the best interests of the Company and its stockholders to liquidate the Company early. PFAC will seek a favorable vote from stockholders at a special meeting to be held later this year. As part of that process, the holders of public shares will have an opportunity to submit their shares for redemption, subject to the provisions of PFAC's Charter. The funds held in trust as of September 30, 2022 were $212,873,704 and the Company expects to return approximately $10.03 per public share to redeeming stockholders, including interest.

17:27 EDT Rio Tinto sees Pilbara iron ore shipments at low end of prior view of 320-335MT - The company states: "Third quarter shipments of 82.9 million tonnes (Rio Tinto share 69.5 million tonnes) were 1% lower than the third quarter of 2021, and 4% higher than the prior quarter despite two unplanned rail outages on the Yandicoogina and Gudai-Darri lines. The investigation into the Gudai-Darri derailment is ongoing. Full year shipments are expected to be at the low end of the original 320 to 335 million tonne range. There were some encouraging performance trends in the third quarter in relation to mine material movements, build-up of run of mine ore stocks and continued ramp up of new projects. Deployment of the Rio Tinto Safe Production System continues to see positive results at West Angelas, Yandicoogina, Tom Price, and Brockman 4."

17:19 EDT Antero Resources to replace Alleghany in S&P 400 at open on 10/20 - Berkshire Hathaway (BRK.A, BRK.B) is acquiring Alleghany (Y) in a deal expected to be completed soon, pending final closing conditions.

17:08 EDT AG Mortgage sees Q3 book value per share between $10.97 and $11.07 - The company "estimates that Book Value per share as of September 30, 2022 was between $10.97 and $11.07, as compared to $11.48 per share as of June 30, 2022. In addition, Adjusted Book Value per share as of September 30, 2022 was estimated to be between $10.63 and $10.73, as compared to $11.15 per share as of June 30, 2022. The Company's liquidity position remains strong, with total liquidity as of September 30, 2022 estimated to be $79.7 million, consisting of $77.6 million of cash and $2.1 million of unencumbered Agency RMBS. The Company's Investment Portfolio as of September 30, 2022 was estimated to be $4.3 billion as compared to $4.1 billion as of June 30, 2022."

16:49 EDT RA Capital Management reports 5.5% passive stake in Adicet Bio - RA Capital Management disclosed a 5.5% stake in Adicet Bio, which represents over 2.36M shares. The filing does not allow for activism.

16:39 EDT FuboTV CEO says pleased with progress to achieving positive cash flow by FY25 - CEO David Gandler says: "FuboTV's strong preliminary third quarter 2022 results reflect meaningful advancements against our continued mission to profitably scale a leading global live TV streaming platform differentiated by the greatest breadth of premium content and interactivity. We expect to deliver strong revenue and subscriber growth in Q3, exceeding our previously issued guidance in North America, against the backdrop of a highly competitive operating environment. We're pleased with this expected performance, and our progress toward achieving our positive cash flow target in 2025. Following our previously announced strategic review, we have concluded that continuing with Fubo Gaming and Fubo Sportsbook in this challenging macroeconomic environment would impact our ability to reach our longer term profitability goals. Therefore, we have made the difficult decision to exit the online sports wagering business effective immediately."

16:37 EDT FuboTV to cease operation of Fubo Sportsbook - The company states: "FuboTV's expected preliminary results demonstrate a continued progression towards the company's 2025 profitability targets. Given these goals, the company has now completed its previously announced strategic review of the Fubo Gaming business. While multiple parties expressed interest in the business, none of these opportunities would have allowed Fubo to lower its funding requirements and generate sufficient returns to shareholders. As a result, FuboTV will close its Fubo Gaming subsidiary and cease operation of its owned-and-operated Fubo Sportsbook effective immediately."

16:32 EDT Corporacion America Airport reports September traffic up 63.5% y/y - Corporacion America Airports reported a 63.5% YoY increase in passenger traffic in September 2022, reaching 85.4% of September 2019 levels. Total passenger traffic grew 63.5% compared to the same month of last year, driven by increases across all countries of operations, particularly in Argentina, supported by a continued recovery in travel demand following the gradual lifting of travel restrictions across all countries of operations. Overall passenger traffic recovered to 85.4% of September 2019 levels, from 83.2% in August, with international and domestic passenger traffic reaching 87.5% and 81.1% of September 2019 levels, respectively.

16:31 EDT SomaLogic appoints Cox as executive chairman of the board of directors - SomaLogic announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board.

16:19 EDT MFA Financial sees September GAAP book value per share $15.25-$15.40 - In light of recent market volatility, MFA Financial, announced preliminary estimates of certain financial measures as of September 30: MFA estimates that on a preliminary basis its GAAP book value at September 30 was between $15.25-$15.40 per common share, as compared to $16.42 per common share at June 30, while its Economic book value, a non-GAAP financial measure was $15.75-$15.90 per common share, as compared to $17.25 per common share at June 31. At September 30, MFA had approximately $435M of unrestricted cash and over $550Mof unencumbered mortgage loans and securities. Estimates that at September 30 approximately 99% of its approximately $7.3B of outstanding asset-based financing was effectively fixed-rate, which includes fixed-rate debt and variable-rate debt that has been economically hedged through interest rate swaps. This compares with approximately 38% at September 30, 2021. In addition, MFA estimates that at September 30, 2022, approximately 71%2 of its asset-based financing was non-mark-to-market. During the Q3 MFA added approximately $650M of new financing capacity for Rehabilitation Loans across multiple counterparties, of which, over $400M is on non-mark-to-market terms. MFA currently has approximately $1.4B of unused financing capacity across all loan product types. Total margin call activity in the Q3 resulted in a net return of cash to MFA from its financing and hedging counterparties.

16:16 EDT Stewart announces retirement of Chief Legal Officer John Killea - Stewart Information Services announced the planned retirement of John Killea, Chief Legal Officer and Chief Compliance Officer, effective early next year. Killea joined Stewart in 2000, serving as Chief Legal Officer and Chief Compliance Officer since 2011. Elizabeth Giddens will succeed Killea as Chief Legal Officer and serve as the Deputy Chief Legal Officer to work alongside Killea during his transition. Giddens comes to Stewart with nearly 25 years of legal expertise, including five years at a top international law firm and 16 years at several public companies, most recently serving as Senior Vice President and General Counsel at Integer Holdings Corporation, where she led its legal department.

16:14 EDT Design Therapeutics to present preclinical data on DT-216 at ICAR 2022 - Design Therapeutics announced that preclinical data for the company's novel GeneTAC small molecule, DT-216, as a potential treatment for Friedreich ataxia will be presented during an oral session at the International Congress for Ataxia Research, ICAR, 2022. The data were included in the company's Investigational New Drug, IND, application for DT-216, which is currently being evaluated in a Phase 1 clinical trial. The preclinical data support the potential for DT-216 to restore FXN gene expression, improve mitochondrial function and address the root cause of FA. Key findings of the presentation include: DT-216 dose-dependently increased FXN in peripheral white blood cells from multiple FA donors and in multiple FA patient cell models; Administration of DT-216 increased FXN mRNA by approximately 10-fold in peripheral blood mononuclear cells collected directly from FA patients; Administration of DT-216 at ~ 10nM, the 90% maximal effective concentration for the molecule, for 14 days in FA patient-derived neurons restored FXN protein to levels comparable to non-FA neurons; DT-216 improved mitochondrial respiration in FA B-lymphoblastoid cells and patient-derived cardiomyocytes as measured using a Seahorse XFp Analyzer; Design is currently evaluating DT-216 in a Phase 1 clinical trial in adult patients with FA. The company plans to report initial data, including safety, tolerability, pharmacokinetics and FXN expression levels from the single-ascending dose portion of the trial in the fourth quarter of 2022.

16:11 EDT Western New England Bancorp completes 2.4M stock repurchase plan - Western New England Bancorp announced that on October 13, the company completed its 2.4M stock repurchase plan at an average price per share of $8.40. The 2021 Plan was authorized on April 27, 2021. On July 26, the board of directors of the company authorized a new stock repurchase plan, pursuant to which the Company may repurchase up to 1.1M shares, or approximately 5%, of the company's outstanding shares, upon the completion of the 2021 plan.

16:08 EDT Beyond Air announces data from at-home pilot study using LungFit GO - Beyond Air, through its affiliate Beyond Cancer, announced "positive" safety, tolerability, and efficacy data from the LungFit GO pilot at-home study of patients with severe, treatment refractory, nontuberculous mycobacteria, NTM, lung disease. "We are pleased to announce that data from the pilot study of the LungFit GO for NTM show favorable outcomes across safety, tolerability, and efficacy endpoints. In addition to further supporting development of intermittent high dose NO for the treatment of NTM, this study breaks new ground in the development of NO therapy by successfully showing the ability of our at-home generator-based system to be used safely and consistently by this patient population in a real-world setting," commented Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. "These data give us confidence that we can move forward as FDA guidance for an NTM pivotal study is to have a patient reported outcome, such as quality of life, for the primary endpoint with supporting secondary endpoints such as a reduction in bacterial load." A total of 15 subjects were enrolled in the pilot study. Four separate strains of NTM were represented across subjects. All subjects were successfully titrated to 250 ppm NO in the hospital setting, and none required dose reductions during the subsequent at-home portion of the study. There were no occurrences of methemoglobinemia and no subjects discontinued NO therapy due to nitrogen dioxide concentrations. During the 10-week at-home treatment period of the study, a total of 2,492 inhalations were self-administered with overall high treatment compliance. Key efficacy endpoints showed strong results with improvement seen in the majority of quality-of-life domains. Respiratory function and physical function were maintained during treatment and follow-up. Trends in the reduction of microbial load were observed as shown in the chart below with statistical significance achieved at the 113/114 day timepoint. One subject achieved culture conversion with three consecutive negative sputum samples.

16:07 EDT Splunk names Sharyl Givens chief people officer - Splunk announced Sharyl Givens has been appointed as the company's Chief People Officer, effective immediately. Givens will be responsible for driving Splunk's "continued success" in attracting, retaining and developing the best talent, the company said. "Driving an inclusive, collaborative, people-focused culture is an important part of what has made Splunk so successful," said Gary Steele, Chief Executive Officer of Splunk. "As we focus on building towards Splunk's next chapter and further strengthening our community, we're pleased to welcome Sharyl to the team. She shares our focus on creating and developing world-class teams with diverse backgrounds, and we look forward to benefiting from her expertise and leadership."

16:06 EDT U.S. Physical Therapy announces impact to operations from Hurricane Ian - U.S. Physical Therapy "announced that the operations of 51 of the Company's 614 clinics were affected by Hurricane Ian. Due to the high winds, loss of electrical power, flooding and road closures attributed to the severe storm, U.S. Physical Therapy's business was interrupted in large parts of the states of Florida, Georgia, and South Carolina. The Company estimates that approximately 3,500 patient visits, representing approximately $300,000 in revenue and gross profit contribution, were lost from September 26 through September 30. An additional 1,100 patient visits, representing approximately $95,000 in revenue and gross profit contribution, were lost in the first week of October."

16:04 EDT BCB Bancorp amends and increases share repurchase program - BCB Bancorp announced that its Board of Directors has amended its current stock repurchase program to increase the number of shares to be repurchased. Under the stock repurchase program as adopted on December 11 the Company was authorized to repurchase up to 500,000 shares of the Company's common stock. As of September 30, 417,650 of those 500,000 shares had been repurchased under the program. The amendment to the stock repurchase program increases the number of shares yet to be repurchased from 82,350 shares to a total number of 500,000 shares. The 500,000 shares authorized to be repurchased under the amended program equate to approximately 2.9% of the Company's outstanding shares of common stock. As of September 30, the Company had approximately 16,973,870 million shares of common stock outstanding.

16:00 EDT Dragonfly Energy Holdings Corp trading resumes

15:43 EDT Dragonfly Energy Holdings Corp trading halted, volatility trading pause

15:26 EDT Netflix launches Profile Transfer to allow users to keep settings if they move - In an earlier blog posting, Product Manager, Product Innovation for Netflix Timi Kosztin said: "People move. Families grow. Relationships end. But throughout these life changes, your Netflix experience should stay the same... we're launching Profile Transfer, a feature that lets people using your account transfer a profile - keeping the personalized recommendations, viewing history, My List, saved games, and other settings - when they start their own membership. This new, much requested feature will roll out to all members around the world starting today. You'll be notified by email as soon as Profile Transfer becomes available on your account." Reference Link

14:22 EDT Allegiant, Viva Aerobus alliance gains Mexico's regulatory approval - Allegiant and Viva Aerobus announced that the Federal Economic Competition Commission unconditionally authorized the Commercial Alliance Agreement between both airlines announced in December 2021. This alliance also includes a strategic equity investment by Allegiant in the Mexican airline. This agreement, a first-of-its-kind in the airline industry between two ultra low cost carriers, will seek to expand low-fare service between Mexico and the United States. Ultimately, this alliance will give the public access to safe and reliable air transport between both countries with a focus on serving destinations that do not currently offer nonstop service This fully-integrated agreement will enable Allegiant and Viva Aerobus to have cross-functionality between their respective loyalty programs, codesharing, sales systems and route networks to operate flights together with all the benefits and advantages of both airlines. Through this alliance, Allegiant, which currently does not serve Mexico, will be able to rapidly enter and expand in the market, while Viva will be able to grow its presence in multiple U.S. markets. The joint application requesting approval and antitrust immunity for the alliance is still pending approval by the U.S. Department of Transportation.

13:30 EDT Globant, FIFA announce multi-year streaming agreement into World Cup - Globant announced this morning a multi-year agreement with FIFA to support the growth of the FIFA+ streaming platform, starting with the FIFA World Cup Qatar 2022. Globant will be the global platform supporter of FIFA+, which launched earlier this year. As part of its responsibilities, Globant will create new features and connected experiences for FIFA+ users while supporting the distribution of the platform, the company said in a statement. In addition, Globant will be a regional supporter of this year's FIFA World Cup in North America and Europe, as well as a sponsor of the FIFA Women's World Cup Australia and New Zealand 202. Globant will also be a FIFA Series global sponsor in 2023, 2024 and 2025, and a worldwide tournament supporter of the FIFA U-17 Women's World Cup 2024, FIFA U-20 Women's World Cup 2024, FIFA U-17 World Cup 2025 and FIFA U-20 World Cup 2025. Shares of Globant are up 4% to $174.17 in afternoon trading.

13:04 EDT CME Group to launch U.S. dollar-denominated TOPIX futures on Nov 21 - CME Group announced it will expand its Tokyo Stock Price Index futures offerings with the launch of U.S. dollar-denominated TOPIX futures on November 21, 2022, pending regulatory review. This new contract will be cash-settled, designed to complement the existing Yen-denominated TOPIX futures contract launched in February 2018. "The addition of U.S. dollar-denominated TOPIX futures represents a natural extension of our Japanese index offerings as we aim to become the primary international venue for trading Japanese equity benchmark products," said Tim McCourt, Global Head of Equity and FX Products, CME Group. "We are pleased to extend our partnership with JPX in launching this new product to provide our customers greater access to Japan's key benchmark, as well as carry that index exposure without FX risk, and have the opportunity to spread against other equity indices."

13:01 EDT Agrify board approves 1-for-10 reverse stock split - Agrify announced that the company's board of directors approved a 1-for-10 reverse stock split, to be effective as of 12:01 a.m. on Tuesday, October 18. The company's common stock will open for trading on the Nasdaq Capital Market on Tuesday, October 18, on a split-adjusted basis under the current trading symbol "AGFY." The reverse stock split was approved by the company's stockholders on October 14 and is intended to increase the per share trading price of the company's common stock to enable the company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

12:03 EDT VMware, First Nations University of Canada launch digital partnership - VMware announced a partnership with the First Nations University of Canada, where it will provide 400 students with complementary access to its transformative digital training program, VMware IT Academy.

12:00 EDT Debt Resolve falls -12.4% - Debt Resolve is down -12.4%, or -$9.97 to $70.41.

12:00 EDT Web Street, Inc. falls -15.1% - Web Street, Inc. is down -15.1%, or -$7.06 to $39.85.

12:00 EDT Seritage Growth Properties rises 22.4% - Seritage Growth Properties is up 22.4%, or $1.86 to $10.17.

11:31 EDT Array Technologies disclosed resignation of COO Kenneth Stacherski - Array Technologies disclosed this morning that on October 11, Kenneth Stacherski, its Chief Operations Officer, provided notice of his intention to resign from his positions as an officer and employee of the company and its subsidiaries, effective as of October 21. Stacherski's resignation is not the result of any material disagreement with the company regarding its operations, policies, or practices, Array said in a regulatory filing.

11:01 EDT BAE Systems to partner on flight control computer for Supernal's eVTOL - BAE Systems and Supernal announced an agreement to design and develop the flight control computer for Supernal's electric Vertical Takeoff and Landing, or eVTOL, vehicle. Work on the flight control system will be conducted at the company's facility in Endicott, New York. "The development of advanced, high-integrity controls is crucial to meet the demands of electric aircraft. BAE Systems is harnessing its investment in electrification and expertise in flight-critical systems to advance sustainable aviation. We look forward to working with Supernal to make this shared vision a reality," said Ehtisham Siddiqui, vice president and general manager of Controls and Avionics Solutions at BAE Systems.

10:36 EDT Preformed Line Products Co acquires Delta Conectores, terms not disclosed - Preformed Line Products Company announced that it has acquired Delta Conectores, S.A. de C.V. Founded in 1979 and based out of Aguascalientes, Mexico, Delta designs and manufactures substation connector systems and accessory hardware for high-voltage AC systems and is a market leader in Mexico. The acquisition of Delta will greatly expand PLP's operational and technical capabilities in the region while supporting its overall global substation strategy.

10:31 EDT Omnicom appoints Andrea Lennon as CCO - Omnicom Group announced the appointment of Andrea Lennon to the new role of Chief Client Officer, effective immediately. Lennon will be responsible for leading Omnicom's multi-disciplinary solutions for enterprise clients, including the company's Global Client Leaders Group that manages and orchestrates client solutions across Omnicom's leading agencies and practice areas. As Chief Client Officer, Lennon will focus on transformative marketing solutions and capabilities that drive business results for global enterprise clients. In partnership with her GCL team, she will accelerate solutions that draw on the Group's best talent while expertly integrating Omnicom's leading capabilities in data, creative, media, communications and technology. Lennon has built a strong track record in marketing transformation at Critical Mass, Omnicom's digital experience design agency, where she spent seven years working in Asia, Europe and the US prior to being named President two years ago.

10:25 EDT EVI Industries to acquire Wholesale Commercial Laundry Equipment - EVI Industries announced that it executed a definitive agreement to acquire Southside, Alabama based Wholesale Commercial Laundry Equipment SE, a distributor of commercial laundry products and a provider of related technical installation and maintenance services to the on-premise and vended laundry segments of the commercial laundry industry. Henry M. Nahmad, EVI's Chairman and CEO, commented: "Each acquisition is integral to achieving our long-term growth and profitability goals." The transaction is expected to close in the second fiscal quarter, subject to the satisfaction of customary closing conditions.

10:00 EDT Direxion Daily Semiconductor Bear 3X Shares falls -9.8% - Direxion Daily Semiconductor Bear 3X Shares is down -9.8%, or -$7.88 to $72.17.

10:00 EDT Executive Network Partnering falls -15.0% - Executive Network Partnering is down -15.0%, or -$1.50 to $8.51.

10:00 EDT Roblox rises 15.1% - Roblox is up 15.1%, or $5.38 to $40.94.

09:54 EDT Insulet issues recall for Omnipod DASH, sees $35M-$45M charge - Insulet disclosed this morning that it issued a voluntary medical device correction notice for its Omnipod DASH Personal Diabetes Manager relating to the Omnipod DASH PDM battery. Insulet will replace the PDMs for all current Omnipod DASH users globally due to reported issues which may occur if the PDM battery is charged to full capacity or for extended periods of time. The Company currently estimates an aggregate charge in the range of $35M to $45M with the majority impacting cost of revenue in Q3 and the remainder primarily impacting operating expenses in Q4 and fiscal year 2023. Additionally, excluding the related charges, the company is not changing its annual gross margin or adjusted operating margin guidance provided on August 4. The voluntary medical device correction notice does not affect the Omnipod DASH Pods, the Omnipod Insulin Management System, or the Omnipod 5 Automated Insulin Delivery System.

09:47 EDT Direxion Daily Semiconductor Bear 3X Shares falls -10.4% - Direxion Daily Semiconductor Bear 3X Shares is down -10.4%, or -$8.34 to $71.71.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas rises 11.5% - ProShares UltraShort Bloomberg Natural Gas is up 11.5%, or $2.05 to $19.82.

09:47 EDT Archaea Energy rises 52.5% - Archaea Energy is up 52.5%, or $8.86 to $25.74.

09:46 EDT 4AIR, Southwest partner to document sustainable aviation fuel use - 4AIR announced that it will provide Sustainable Aviation Fuel inventory accounting and documentation services for Southwest Airlines. In October 2021, the carrier announced a series of near-term goals, actions, and initiatives in support of a 10-year plan to maintain carbon neutrality to 2019 levels while continuing to grow its operations. This includes a goal of replacing 10 percent of its total jet fuel consumption with sustainable aviation fuel by 2030. SAF is a key strategy to address the carbon emissions generated by the aviation industry associated with climate change. Under the agreement, 4AIR will support Southwest with allocating and documenting certain Scope 3 emission reduction rights arising from Southwest's use of SAF for corporate clients participating in its SAF Beta Program. These clients purchase Scope 3 emission reduction rights arising from Southwest's use of SAF, which contributes to reducing the premium of SAF over conventional jet fuel and helps send demand signals to the market.

09:39 EDT TOP Financial Group Ltd trading resumes

09:34 EDT TOP Financial Group Ltd trading halted, volatility trading pause

09:32 EDT Sinclair Broadcast enters creative partnership with Anthony Zuiker - Sinclair Broadcast Group announced a broad, multi-platform creative partnership with Anthony E. Zuiker to create content across a range of formats and subjects. Zuiker, an award-winning content creator, writer, and producer, best known as the creator of the global hit franchise, CSI: Crime Scene Investigation, will work with Sinclair's CIO Scott Ehrlich, and the Sinclair team, to develop original programming and content. Working with Sinclair's news teams, across its 185 owned/operated television stations, Zuiker will highlight the compelling stories that deserve to be told in a longer, more dynamic format, broadening the appeal for a global audience. Zuiker will also develop content that can live adjacent to news programming and across ancillary verticals. Potential programming categories include docuseries, game shows and topical talk.

09:28 EDT SHF Holdings selected as preferred facilitator for financial services to ATACH - SHF Holdings announced it has been selected as the preferred facilitator for financial compliance, validation, and onboarding services for the American Trade Association for Cannabis & Hemp, an organization that promotes the expansion, protection, and preservation of businesses engaged in the legal trade of industrial, medical, and recreational cannabis and hemp based products. "The partnership with ATACH will help deliver compliant financial solutions for licensed cannabis operators by making available to all of its members access to financial services through our financial institution clients and using our compliance and onboarding services," stated Sundie Seefried, Founder and CEO of Safe Harbor. "As the premier cannabis-focused financial solutions provider to the cannabis industry, we are strongly positioned to assist the industry's most influential trade organization."

09:25 EDT Imperial Petroleum announces adjournment of annual meeting - Imperial Petroleum announced that the Annual Meeting of Shareholders of the Company reconvened on October 13, 2022, has been adjourned, due to lack of requisite quorum, and rescheduled to Tuesday, December 20, 2022 at 11:00 a.m. Greek local time at the Company's offices at 331 Kifissias Avenue, Erithrea 14561 in Athens, Greece.

09:17 EDT Airgain names Michael Elbaz as CFO - Airgain (AIRG) announced the addition of Michael Elbaz as CFO and secretary. Elbaz brings over twenty five years of experience in corporate and global finance and strategy. As CFO, Elbaz will lead Airgain's accounting, financial planning and analysis, treasury, investor relations and information technology functions. Prior to joining Airgain, Mr. Elbaz was VP Finance at Cohu (COHU).

09:16 EDT Imax and Wanda sign nine-theater agreement in China - Imax and Wanda Film, China's largest exhibitor, announced a nine-theatre deal spanning key Chinese markets. Under the agreement, six new Imax systems will be installed in newly built multiplexes across key Chinese markets. Additionally, Wanda will relocate and upgrade three of its existing IMAX systems to forthcoming new multiplexes. It is Imax 's first agreement for more than five new theatres in China since February 2021.

09:14 EDT AbbVie's Chief Legal Officer Laura Schumacher retiring - AbbVie announced that Laura Schumacher, vice chairman of external affairs and chief legal officer, will retire from the company after a period of transition, following a 32-year career at AbbVie and its predecessor company Abbott. Perry Siatis, who currently serves as senior vice president and deputy general counsel, will assume the role of executive vice president, general counsel and secretary. Siatis joined the legal department of Abbott Laboratories in 2005 and advanced through a series of leadership roles with increasing responsibility at Abbott, and then AbbVie. Siatis has also served as chief compliance officer.

09:12 EDT Bank of America expects Q4 tax rate 'similar' to Q3, says CFO

09:09 EDT European Biotech Acquisition, Oculis enter business combination agreement - Oculis and European Biotech Acquisition Corp announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named "Oculis Holding SA" and will work to accelerate the development of Oculis's differentiated ophthalmology pipeline. The transaction includes commitments to an upsized PIPE and private investment of close to $80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others. The business combination is expected to deliver gross proceeds to Oculis in excess of $200 million. This includes approximately $127.5 million held in EBAC's trust and commitments to an upsized PIPE and private investment of close to $80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others. The proposed transaction was unanimously approved by the board of directors of all parties and is supported by existing shareholders of Oculis. The proposed transaction is expected to be completed in the first half of 2023, subject to, among other things, the approval by EBAC shareholders and the satisfaction or waiver of other customary closing conditions. The newly listed entity Oculis Holding SA will be a company registered in Switzerland with its headquarters at the current office of Oculis at the EPFL Innovation Park in Lausanne, Switzerland.

09:05 EDT LegalZoom acquires document automation, forms template company Revv - LegalZoom.com has acquired Revv, a Global SaaS, Bangalore, India based document automation and forms template company. Revv's proprietary technology will enhance LegaZoom's forms library and legal templates offerings and will be used to develop modern product experiences and services for small businesses. "The acquisition of Revv demonstrates our continued focus on scaling critical engineering and product talent to deliver the best products and services for small businesses," said Dan Wernikoff, CEO of LegalZoom. "The addition of Revv through this transaction also gives us access to the attractive Bangalore talent market, and will ultimately help us deliver on our business priorities as we head into 2023." Revv offers legally binding eSignatures coupled with vetted templates, cloud-based workflow automation, native API, Zapier integration, analytics, cloud-based storage, and audit trails.

09:05 EDT Straight Talk Home Internet now available at Walmart - Introducing Straight Talk Home Internet: an affordable, no-contract, no-credit-check, prepaid fixed wireless internet service, available exclusively at Walmart (WMT). Straight Talk, known for providing incredible value in prepaid wireless with the unmatched distribution of Walmart, continues to deliver with Straight Talk Home Internet. This new service will help more consumers bridge the divide to the digital world by making high-speed broadband more affordable and attainable for those that need reliable internet, but prefer no contracts, no credit checks and a broader choice in payment options - including cash. Straight Talk Home Internet takes advantage of Verizon's (VZ) award-winning 5G and 4G LTE networks. At just $45 per month, it offers unlimited 5G / 4G LTE data with speeds up to 100 Mbps on 5G or 50 Mbps on 4G LTE, and Wi-Fi 6 Dual-band. The easy, self-set-up router is only $99 and can connect multiple devices. Straight Talk Home Internet will be available at nearly 2,000 Walmart stores across the country and at Walmart.com and StraightTalk.com.

09:04 EDT Sorrento Therapeutics completes Phase 1 study of STI-1558 - Sorrento Therapeutics announced the completion of a Phase 1 study of its oral main viral protease inhibitor, the STI-1558 in 58 healthy volunteers. The Phase 1 safety and PK study in healthy volunteers was conducted in Australia. The study is entitled: "A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of STI-1558 in Healthy Volunteers." In the SAD portion of the study, 4 dose-escalation cohorts were conducted with 8 subjects in each cohort, randomized 3:1. In the MAD portion of the study, 3 dose-escalation cohorts with daily doses of 300 mg BID, 600 mg BID or 800 mg BID for consecutive 7.5 days were conducted with 8 subjects in each dose cohort randomized 3:1. The preliminary blinded safety and PK data from the SAD and MAD portions of the study are available. Overall, there were no changes in vital signs, physical examinations, ECGs or safety clinical labs resulting from study participation. The linear and semi-log plots for doses from 300 mg to 2000 mg are proportional in the SAD portion. In the 600 mg BID dose cohort of the MAD portion, the trough concentration was significantly above the EC90 value of predicted value for viral inhibition and no accumulation was seen, supporting a 600 mg twice-daily dose as a recommended dose for standalone treatment without ritonavir booster. A phase 1 trial in participants infected with SARS-CoV-2 has been initiated in China, and a total 56 participants will be enrolled to assess the safety, tolerability, and efficacy in 3 MAD dose cohorts. Eight participants infected with SARS-CoV-2 in the first MAD dose cohort of 300 mg BID have been dosed. A large Phase 2 registrational study is planned in Mexico that could support an Emergency Use Authorization in Mexico with potential for distribution throughout Latin America. Registrational Phase 2/3 trials in US, China and other major regions have also been planned.

09:02 EDT Medtronic's cardiac pacing system receives FDA approval - Medtronic has received FDA approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy. Commonly referred to as "conduction system pacing," this approach helps ensure that pacing closely mimics the heart's physiologic contractions, allowing the heart's ventricles to work in coordination. Medtronic is the first and only company with therapies approved for conduction system pacing. In 2018, the FDA approved the SelectSecure MRI SureScan cardiac lead for His-Bundle pacing, another form of conduction system pacing.

09:02 EDT MKS Instruments releases second annual ESG report - MKS Instruments released its second annual Environmental, Social, Governance, ESG, Report, which highlights MKS' commitment to ESG issues. "For MKS, achieving a more sustainable future means drawing upon our culture of human curiosity and ingenuity to solve problems and deliver solutions," said John Lee, President and CEO of MKS. "Our commitment to operating our business in an environmentally and socially responsible manner, in tandem with our employees, customers, suppliers and communities, remains unwavering." This Report details the progress MKS has made toward the achievement of key ESG objectives. Highlights include: Instituting a formal Global MKS Management System for Environmental, Health, and Safety to protect MKS' employees, other stakeholders, and the environment; Expanding disclosure of Scope 3 emissions and tracking additional Scope 3 categories; Expanding Diversity, Equity and Inclusion-specific training to all employees globally; Setting DE&I goals for executives; Conducting an analysis of global employees' compensation that resulted in equitable pay for employees.

09:00 EDT Minerva trading resumes

08:53 EDT Bank of America CFO sees deposit rates increasing

08:51 EDT Prospect Capital announces launch of cash tender offer - Prospect Capital Corporation announced that it has commenced a cash tender offer to purchase any and all of the outstanding notes listed below. The Tender Offer will expire at 5:00 p.m., New York City time, on October 21, 2022, or any other date and time to which the Company extends the Tender Offer. The Tender Offer is made pursuant to an Offer to Purchase dated today and related notice of guaranteed delivery, which set forth the terms and conditions of the Tender Offer. The consideration to be paid for each $1,000 principal amount of Notes that are validly tendered and not validly withdrawn on or prior to the Expiration Time is $985.00, plus accrued and unpaid interest on the Notes, if any, from the applicable last interest payment date up to, but not including, the Settlement Date. The Company will purchase any Notes that have been validly tendered at or prior to the Expiration Time and accepted for purchase, subject to all conditions to the Tender Offer having been either satisfied or waived by the Company, promptly following the Expiration Time. Assuming the Tender Offer is not extended, the Company expects that the Tender Offer will settle and payment will be made on October 26, 2022.

08:48 EDT Minerva to resume trading at 09:00 ET - Minerva is set to resume trading at 9:00 am ET, with quotation scheduled to resume at 8:55 am ET, according to Nasdaq. Shares had been halted, pending news, ahead of the company announcement that it had received a refusal to file letter from the FDA regarding the company's New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

08:46 EDT Omniq named total solution partner for enterprise asset intelligence company - OMNIQ Corp. announced that the company has been named a Total Solution Partner for one of the Largest Global Companies in Enterprise Asset Intelligence. OMNIQ's comprehensive offering will be utilized for manufacturing, fulfilment and distribution solutions. The company, together with their partner allows for quick decision making with easy-to-use robotics management software delivering a fully automated warehouse.

08:43 EDT Jaguar Health announces Orphan Drug Designation from EMA for corfelemer - Jaguar Health and Napo Therapeutics announced that the European Commission has adopted the decision to grant Orphan Drug Designation for crofelemer for the indication of microvillus inclusion disease, a rare congenital diarrheal disorder condition, in the European Union following review of the ODD application Napo Therapeutics submitted to the European Medicines Agency in May 2022.

08:42 EDT Bank of America card delinquencies remain below pre-pandemic levels, says CEO

08:41 EDT NetSol Technologies announces EMBank goes live with Flex - NETSOL Technologies has announced that European Merchant Bank has signed up for and gone live with Flex - NETSOL's latest product offering. Flex is an instant cloud-based calculation engine for out-of-the-box integration into an organization's products, services and ecosystem. The agreement for this sign-up and go-live covers the deployment of the calculation engine for the bank's operations in Lithuania, Eastern Europe. "I am extremely pleased to announce this signing-up, and subsequently, immediate access of Flex for the client," said Kamran Khalid, Chief Product Officer at NETSOL Technologies. "While EMBank operates as a digital bank, their sales personnel provided pricing quotations to their customers which differed on their core systems. This is where our pure-play SaaS product comes in, with its ability to ensure a seamless and superior user experience and the cloud-based solution's penny-accurate calculations at all stages of the contract lifecycle and through various calculation types," he added. "The product is a one-stop solution which can be implemented over multiple systems, essentially removing the difference in pricing quotations provided since the same calculation engine is being used on many systems." "With an onboarding time of a mere 5 minutes and availability through flexible, subscription-based pricing, the client's pricing reconciliation issues were instantly resolved," he also stated. "This enables the bank's sales personnel to now provide numbers which will automatically match the core system results. Flex accelerates growth by increasing delivery efficiency and product management, centralization through a connected ecosystem resulting in higher ROI and a larger market share."

08:39 EDT Enochian Biosciences awarded U.S. patent for oncology platform - Enochian BioSciences announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world's deadliest solid tumors. In addition, Dr. Anahid Jewett, professor and director of tumor immunology laboratory at UCLA performed key proof-of-concept preclinical animal and laboratory studies of the Company's product candidate to treat pancreatic cancer in humanized mice model of hu-BLT that have yielded positive and promising results. Additional IND-enabling studies are in progress. If results remain positive, the Company believes it will potentially submit a Pre-IND application to the FDA by early- to mid-2023, followed by IND submission and human trials planned for the end of 2023 or early 2024. The Company hopes to expand its oncology treatment platform to product candidates that could include triple-negative breast cancer, glioblastoma, and/or renal cell carcinoma. "We are incredibly excited to have been awarded this patent for Enochian's allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results," said Enochian's CEO Dr. Mark Dybul. "This technology could be transformative for oncology and for treating some of the world's deadliest cancers, including pancreatic cancer, which has a five-year survival rate of just five to ten percent. Because there are few therapeutic options, we hope to pursue Fast-Track designation to potentially help accelerated access for persons with pancreatic cancer. We are fully committed to continued research and development of this platform as rapidly as possible as our lead product candidate."

08:39 EDT BofA's wealth unit opened record number of accounts in Q3, says CEO

08:37 EDT Vision Systems demonstrates use of SPD-SmartGlass products - Vision Systems, a Gauzy company and licensee of SPD-Smart light control technology developer Research Frontiers will demonstrate the extensive use of SPD-SmartGlass products for the transportation industry at the NBAA-BACE show in Orlando. At the October 18-20 NBAA aerospace show, Vision Systems will be highlighting many of their projects using SPD-SmartGlass at Booth #3488. These projects include 17 aerospace programs, 9 marine programs, 9 specialty vehicle programs, 3 railway programs, and 3 recreational vehicle programs.

08:36 EDT Roblox reports September DAUs 57.8M, up 23% - Roblox released certain key metrics for the month of September. Daily active users, or DAUs, were 57.8M, up 23% year-over-year. Hours engaged were 4B, up 16% year-over-year. Estimated bookings were between $212M and $219M, up 11%-15% year-over-year. Estimated average bookings per daily active user were between $3.67 and $3.79, down 7%-10% year-over-year. Estimated revenue was between $171M and $180M, which represents a year-over-year change of down 2% to up 3%.

08:35 EDT Edible Garden announces appointment of Pawlowski to board of directors - Edible Garden announced the appointment of Deborah Pawlowski to the Edible Garden Board of Directors, effective October 14, 2022. Pawlowski has been appointed to the Audit Committee, Compensation Committee, and Nominating and Governance Committee of the Board and has been appointed as Chair of the Compensation Committee. Pawlowski brings more than thirty years of experience in investor relations, capital markets, marketing, strategic planning, leadership coaching and management. For over 20 years, she has served as the Founder, Chairman and CEO of KEI Advisors, an investor relations and business advisory firm.

08:35 EDT Color Star Technology's metaverse platform adopted by Thailand's Grand Siri REIT - Color Star Technology announced a new strategic cooperation with Thai real estate company Grand Siri. Grand Siri will join the company's ColorWorld Metaverse platform, where Grand Siri will set up a metaverse headquarter and promote its brand with the help of the platform. In the future, Grand Siri will list its real estate projects in the metaverse to meet global housing demands. Users will be able to view and purchase properties online. The two companies will be focused on the topics of online real estate sales, user conversion and diversion, corporate brand enhancement, etc.

08:34 EDT Point Biopharma publishes preclinical data for actinium-labelled PNT2001 - POINT Biopharma Global announced the publication of promising new pre-clinical data from the Company's next-generation radioligand therapy program for prostate cancer, PNT2001. "We are entering an exciting stage in POINT's prostate cancer franchise," said Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma. "Our PNT2001 actinium-225 program exemplifies our team's deep expertise in the rapid development of new and innovative radioligands. And while we are advancing the next generation of PSMA-targeted radioligand therapy, we are simultaneously continuing our pre-commercial planning for our lead asset, PNT2002, by evaluating the most capital efficient approaches to commercialization including resourcing of internal commercial capabilities and exploring strategic commercial partnership options." PNT2001 builds on POINT's first-generation, lutetium-based program with a next-generation ligand optimized for use with the alpha-emitting radioisotope actinium-225. The new PNT2001 data were shared in E-poster #039, "Development and characterization of a next-generation 225Ac-PMSA radioligand", at the 35th Annual Congress of the European Association of Nuclear Medicine, currently taking place in Barcelona, Spain. In pre-clinical models, 225Ac-PNT2001 demonstrated: Increased internalization by tumor cells in vitro, compared to that of a first-generation ligand; More precise tumor targeting in vivo, leading to a promising safety profile in murine models; Compelling therapeutic activity, including suppression of tumor growth and metastases, along with improved survival, following the administration of a single dose in mice. These pre-clinical findings support the advancement of 225Ac-PNT2001 to clinical evaluation.

08:32 EDT Enanta doses first subject in Phase 1 study of EDP-323 - Enanta Pharmaceuticals earlier announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus, or RSV. This randomized, double-blind, placebo-controlled, first-in-human Phase 1 study will enroll approximately 80 healthy subjects ranging in age from 18 to 65 years old to evaluate the safety, tolerability and pharmacokinetics of EDP-323 with a single-ascending dose phase, including a two-part food-effect cohort, and a multiple-ascending dose phase. All SAD and MAD cohorts will enroll eight participants who will be randomized to receive EDP-323 or placebo in a 3:1 ratio. The SAD/FE cohort will enroll 10 subjects randomized in a 4:1 ratio. "This first-in-human study of EDP-323, our selective, direct-acting antiviral specifically targeting the RSV L-protein, is an important milestone for Enanta as we mark the continued expansion of our clinical RSV portfolio. Compelling preclinical data show that EDP-323 potently blocks RSV replication and pathology across all RSV genotypes positioning EDP-323 as a potentially best-in-class potent oral antiviral treatment for RSV. EDP-323 could be used as a monotherapy or in combination with other RSV mechanisms, such as EDP-938, to broaden the addressable patient populations or treatment windows. As we continue to build upon our leadership in the RSV space, we believe having two unique mechanisms to treat the virus could potentially provide additional benefit to patients," said Scott Rottinghaus, M.D., Senior Vice President and Chief Medical Officer of Enanta.

08:32 EDT MSA Safety appoints Lee McChesney as CFO - MSA Safety has named Lee McChesney as Senior VP and CFO. McChesney previously served as VP, Corporate Finance and CFO for Stanley Black & Decker's operating unit, Global Tools and Storage. McChesney joined The Stanley Works in 1999. He also served as the finance integration leader for The Stanley Works and Black & Decker merger in 2010. In his role with MSA, McChesney succeeds interim CFO Jonathan Buck, who will resume his responsibilities as Chief Accounting Officer.

08:29 EDT Ollie's Bargain Outlet appoints Rob Helm as CFO - Ollie's Bargain Outlet Holdings (OLLI) announced the hiring of Rob Helm to the position of SVP and CFO, effective immediately. Rob will report to John Swygert, President and CEO, and will lead the Accounting, Financial Planning and Analysis, Financial Reporting and Compliance, and Investor Relations teams. Rob joins Ollie's from The Children's Place (PLCE), where he most recently served as CFO.

08:21 EDT Titan Aircraft Investments, ASL Aviation announce long-term dry lease agreement - Titan Aircraft Investments, the joint venture between Titan Aviation Holdings and Bain Capital Credit, announced the placement of a Boeing (BA) 737-800SF converted freighter on long-term dry lease with ASL Aviation Holdings. Titan Aviation Holdings, a subsidiary of Atlas Air Worldwide Holdings (AAWW), will manage the aircraft. "We are honored that ASL has placed its trust in Titan and we look forward to growing our new partnership in the future," said Michael Steen, President and Chief Executive Officer of Titan Aviation Holdings and Chief Commercial Officer of Atlas Air Worldwide.

08:20 EDT PayPal announces 'PayPal Rewards,' a new unified rewards program - PayPal announced the introduction of PayPal Rewards, a new unified rewards program that gives customers an easy way to shop, earn, track, save, and redeem rewards and offers all in one place - their PayPal app. PayPal Rewards connects PayPal's merchant offers, cash back savings, and shopping products into one experience. PayPal Rewards provides a ubiquitous rewards program, where consumers can earn PayPal Rewards points and save money through cash back and discounts at participating retailers. PayPal Rewards will build upon the nearly $200M PayPal consumers have already saved this year so far through PayPal Honey-enabled cash back and discounts. With the introduction of PayPal Rewards, Honey Gold will become PayPal Rewards points. Customers will have the option to set up or link to an existing PayPal account and start benefiting from this new integrated experience with more ways to redeem their rewards points.

08:16 EDT Boxed expands Boxed Market to Westchester County, NY - Boxed announced it is expanding Boxed Market, its rapid delivery of fresh groceries business. Boxed Market has just opened a new fulfillment center in Elmsford, NY, to serve customers in Westchester County. In December of 2021, Boxed acquired MaxDelivery, one of the first on-demand grocery delivery services to provide New Yorkers a broad assortment of groceries to their door in under one hour. The 18 year-old business, loved by customers because of its "no product substitutions" approach, was rebranded as Boxed Market earlier this year. The new fulfillment center in Westchester County is larger than the existing Manhattan location, as Boxed Market has been steadily growing its selection and offerings to meet customer demand.

08:15 EDT Rumble releases app notifications for iOS, Android - Rumble announced that the company has launched notifications for the company's iOS and Android applications. The new feature will allow creators to notify their subscribers instantly about livestreams. As a result, creators will be able to grow their audiences, drive engagement on their content and ultimately generate more earnings. You can download the Rumble iOS app and Android app is each of the respective stores.

08:13 EDT AMMO planned launch of proprietary eCommerce payment - AMMO announces it is scheduled to launch its proprietary eCommerce payment processing platform on or about January 1, 2023. In targeting the acquisition of the GunBroker.com family of companies and world class Marketplace in 2021, one of the many identified leveraging and enhancement opportunities the Board and management identified was the ability to bring in-house a more streamlined and efficient proprietary payment processing system which would serve two critically important purposes: substantially improve the Marketplace experience for buyers and sellers alike, and; drive substantial additional revenue, and more importantly, net income to the Company's bottom line through the orderly contract compliant transition away from and ultimate elimination of unnecessary and costly 3rd party processing relationships such as BitRail in the first two calendar quarters of 2023. The Company is pleased to announce it has targeted the launch of this new service for January 1, 2023. In partnership with a premier gateway accessing the major credit card issuers in real time, GunBroker.com' proprietary ecommerce payment processing suite will allow the Company to control all transactional payment processing elements of the buying and selling of products offered on the GunBroker.com Marketplace. The new service will include secure identification and fraud security tools, invoicing, and valuable loyalty programs that support sellers to help them grow their business with data analytics and marketing support we don't see available within the market.

08:10 EDT Global Crossing Airlines enters Phase 2 for certification of GlobalX-Colombia - Global Crossing Airlines Group announced the start of Phase 2 of the Colombia AOC Certification Process by GlobalX-Colombia. Initial approval from the Colombian CAA to start the formal certification was received in June of this year. GlobalX-Colombia is a 100% owned subsidiary of GlobalX and is led by Roberto Held, former CFO of Avianca and now a senior advisor to GlobalX who will become CEO of the subsidiary upon final certification. In the coming weeks GlobalX-Colombia will be submitting all Flight Operations, and Maintenance/Technical Manuals for Phase 2 for review by the Colombian Civil Aviation Authority. The certification process is being led in Bogota by a team of experts and advisors with these matters. Final AOC approval is expected by the end of Q1 2023 when GlobalX will assign A321 freighters from its US operation to the Colombian AOC.

08:10 EDT Dow Inc. to accelerate sustainability targets the company set in 2020 - Dow Inc. announced it will accelerate the sustainability targets the company set in 2020 by expanding its Stop the Waste target to a Transform the Waste target. By 2030, Dow will transform plastic waste and other forms of alternative feedstock to commercialize 3M metric tons of circular and renewable solutions annually. To do this, Dow will expand its efforts to stop the waste by building industrial ecosystems to collect, reuse or recycle waste and expand its portfolio to meet rapidly growing demand. It is expected that the waste required to produce 3M metric tons of circular and renewable solutions per year by 2030 will surpass and replace Dow's original 1M metric ton goal.

08:09 EDT Gracell doses first patients in Phase 2 trial of leukemia candidate GC007g - Gracell announced that the first patient has been dosed in the Phase 2 portion of its registrational Phase 1/2 clinical trial evaluating GC007g for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia - r/r B-ALL - being conducted in China. GC007g is Gracell's allogeneic, human leukocyte antigen-matched, donor-derived, CD19-directed CAR-T cell therapy candidate under development for the treatment of a subset of B-ALL patients who relapsed after allogeneic human stem cell transplant. Data from the Phase 1 trial showed encouraging efficacy and a favorable safety profile. The registrational Phase 2 trial is being conducted in China and will further assess the safety and efficacy of GC007g in r/r B-ALL patients at the recommended Phase 2 dose.

08:08 EDT Barnwell Industries adopts Tax Benefits Preservation Plan - Barnwell Industries announced that its Board of Directors has adopted a Tax Benefits Preservation Plan designed to protect the availability of the Company's existing net operating loss carryforwards and certain other tax attributes. The Company has generated substantial Tax Benefits, which could potentially be used in certain circumstances to reduce its future income tax obligations. Utilization of these NOLs and other Tax Benefits depends on many factors, including the Company's future taxable income. Additionally, the Company's ability to use its Tax Benefits would be substantially limited if it were to experience an "ownership change," as defined under Section 382 of the Internal Revenue Code of 1986, as amended. In general, a corporation would experience an ownership change if the percentage of the corporation's stock owned by one or more "5% stockholders," as defined under Section 382, were to increase by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The purpose of the Tax Plan is to reduce the likelihood that the Company will experience an ownership change under Section 382, which would limit the Company's future use of its Tax Benefits and, in turn, significantly impair the value of such Tax Benefits. Absent the adoption of the Tax Plan, the Company would be at a greater risk of experiencing an ownership change under Section 382 in the future as a result of certain changes in its investor base and subsequent shifts in its stock ownership that cannot be predicted or controlled. If the Company were to undergo an ownership change, limitations would be placed on the Company's ability to utilize the Tax Benefits in future years in which it has taxable income, and the Company would pay more taxes than if it were able to utilize the Tax Benefits fully. This could result in a negative impact on the Company's financial position, results of operations, and cash flows. The Tax Plan is designed to preserve the Tax Benefits by reducing the risk of an ownership change under Section 382. The Tax Plan adopted by the Board is similar to plans adopted by other publicly held companies with substantial Tax Benefits and has a limited duration of three years. The Tax Plan is not designed to prevent any action that the Board determines to be in the best interest of the Company and its stockholders. To implement the Tax Plan, the Board declared a dividend of one right for each outstanding share of the Company's common stock. The Rights will be issued to stockholders of record at the close of business on October 27, 2022 pursuant to the Tax Plan. The Rights will be exercisable if a person or group of persons acquires 4.95% or more of the Company's common stock. The Rights will also be exercisable if a person or group of persons that already owns 4.95% or more of the Company's common stock acquires an additional share other than as a result of a dividend or a stock split. Existing stockholders that beneficially own in excess of 4.95% of the Company's common stock will be "grandfathered in" at their current ownership level. If the Rights become exercisable, all holders of Rights, other than the person or group of persons triggering the Rights, will be entitled to purchase shares of the Company's common stock at a 50% discount. Rights held by the person or group of persons triggering the Rights will become void and will not be exercisable. The Tax Plan also includes an exchange option. At any time after any person or group of persons acquires 4.95% or more of the Company's common stock, but less than 50% or more of the outstanding shares of the Company's common stock, the Board, at its option, may exchange the Rights, in whole or in part, at an exchange ratio of three shares of the Company's common stock per outstanding Right. The Rights will trade with the Company's common stock and will expire at the close of business on October 17, 2025. The Rights will expire under other circumstances as described in the Tax Plan, including on the date set by the Board following a determination that the Tax Plan is no longer necessary or desirable for the preservation of the Tax Benefits or no significant Tax Benefits are available to be carried forward or are otherwise available. The Board may terminate the Tax Plan prior to the time the Rights are triggered or may redeem the Rights prior to the Distribution Date, as defined in the Tax Plan.

08:06 EDT SVB Financial hires Laura Cushing as Chief Human Resources Officer - SVB Financial appointed Laura Cushing as Chief Human Resources Officer. Cushing succeeds Chris Edmonds-Waters who held the CHRO position since 2007 and is transitioning into an executive coaching role for the company. Cushing joins SVB from diversified holding company Loews Corporation, where she served as CHRO since 2016. Prior to Loews, Cushing spent more than 20 years in senior leadership positions at JPMorgan Chase & Co., including Head of Talent Management & Organizational Development for Chase.

08:05 EDT Fennec announces commercial availability of PEDMARK in U.S. - Fennec Pharmaceuticals announced the U.S. commercial launch and availability of PEDMARK to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. "We are proud to announce that PEDMARK is now available to pediatric patients and their physicians who are in need of options to help reduce the risk of cisplatin-induced hearing loss," said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals. "Children who get platinum-based chemotherapy, such as cisplatin, are at risk for permanent hearing loss, a condition that previously could only be managed with cochlear implants and hearing aids. PEDMARK provides the first and only FDA-approved treatment specifically designed to help protect hearing in children and young adults after receiving cisplatin. We look forward to engaging with healthcare providers and supporting patient access to this breakthrough therapy with our assistance program, Fennec HEARS." The Company has established Fennec HEARS, a comprehensive single source program designed to connect PEDMARK patients to both patient financial and product access support. The program offers assistance and resources, regardless of insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met. PEDMARK was approved by the U.S. Food and Drug Administration in September 2022 based upon safety and efficacy data from two pivotal open-label, randomized Phase 3 trials, which compared PEDMARK plus cisplatin-based regimen to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients. The Marketing Authorization Application for sodium thiosulfate is currently under evaluation by the European Medicines Agency. Prior to its approval in the U.S., the FDA granted PEDMARK Priority Review designation in 2020 and Orphan Drug designation in 2004.

08:04 EDT Rumble Ad Center releases beta version of pre-roll video ads - Rumbleannounced that the company has launched a beta version of pre-roll video ads on the Rumble Advertising Center. In addition to display ad formats currently available on the Rumble Advertising Center, pre-roll video ads allow advertisers a new way to access Rumble traffic directly and create pre-roll video campaigns. For creators, combining display and video ads on the Rumble Advertising Center will translate into growing CPMs and payouts on the platform, which they will begin seeing on their Rumble dashboards.

08:03 EDT American Outdoor Brands files patent, trademark infringement complaint - American Outdoor Brands filed a complaint on September 23 against Good Sportsman Marketing, or GSM, alleging that GSM's use of the Leadsled, Tackdriver, and Dead Shot marks constitute trademark counterfeiting and trademark infringement as well as alleging that GSM is infringing American Outdoor Brands' patent rights incorporated in the Lead Sled shooting rest through GSM's sale of the Alpha Shooting Rest. The complaint was filed in Delaware federal court and seeks injunctive relief and monetary damages. Birchwood Casey, a division of GSM, began selling a Lead Sled weight bag, Tackdriver rest bag, and a Deadshot shooting rest bag without the permission or authorization of American Outdoor Brands. American Outdoor Brands registered these trademarks with the USPTO over 14 years ago. Birchwood Casey's products are not authorized by, or affiliated with American Outdoor Brands. American Outdoor Brands is seeking an order requiring GSM to withdraw these products from the market, among other relief.

08:01 EDT Koppers Holdings to acquire Gross & Janes Co., terms not disclosed - Koppers Holdings announced that Koppers Inc., a wholly-owned subsidiary of Koppers Holdings, has signed a definitive agreement to acquire substantially all of the assets of Gross & Janes Co. for an undisclosed amount. The transaction is expected to close within the next thirty days, subject to customary closing conditions. Gross & Janes, headquartered in Kirkwood, Missouri, is the largest independent supplier of untreated railroad crossties in North America, with operations in Williamsville, Missouri, and Camden, Arkansas.

07:59 EDT A2Z Smart Technologies announces withdrawal of short form base shelf prospectus - A2Z Smart Technologies announces that it has decided to voluntarily withdraw the amended and restated preliminary short form base shelf prospectus of the Company that was filed on July 26, 2022, due to among, other things, market conditions.

07:41 EDT Vicinity Motor announces $100M+ purchase order for 1K electric trucks - Vicinity Motor announced the receipt of a purchase order for 1,000 VMC 1200 Class 3 Electric Trucks from Pioneer Auto Group - Vicinity's exclusive dealer in the province of British Columbia, Canada. Per the terms of the PO, which exceeds US$100M in revenue, Vicinity is to deliver a minimum of 1,000 VMC Class 3 Electric Trucks by the end of 2023. Deliveries under the PO are expected to commence this month.

07:40 EDT Vicinity Motor seceures over $100M purchase order for VMC 1200 Electric Trucks - Vicinity Motor announced the receipt of a purchase order for 1,000 VMC 1200 Class 3 Electric Trucks from Pioneer Auto Group - Vicinity's exclusive dealer in the province of British Columbia, Canada. Per the terms of the PO, which exceeds $100 million in revenue, Vicinity is to deliver a minimum of 1,000 VMC Class 3 Electric Trucks by the end of 2023. Deliveries under the PO are expected to commence this month.

07:39 EDT Just Energy intends to proceed with Stalking Horse Transaction - Just Energy Group announced that the previously announced sales and investment solicitation process has concluded and the previously announced transaction contemplated by the stalking horse transaction agreement entered into on August 4, 2022 among Just Energy and the lenders under the Company's debtor-in-possession financing facility, one of their affiliates and the holder of certain assigned secured claims was the successful bid pursuant to the SISP. No bids meeting the criteria prescribed by the SISP were submitted by the deadline of October 13, 2022. Just Energy and certain of its affiliates intend to file a motion in their proceedings under the Companies' Creditors Arrangement Act before the Ontario Superior Court of Justice for an Order that, among other things, approves the transactions provided for under the Stalking Horse Transaction Agreement, which is described further below. The Just Energy Entities also intend to seek recognition in the U.S. of the Vesting Order in their Chapter 15 case in the Bankruptcy Court of the Southern District of Texas, Houston Division on December 1, 2022. Subject to the granting of the Vesting Order at the motion scheduled for November 2, 2022 and the satisfaction or waiver of the other conditions to closing, upon the closing of the Stalking Horse Transaction, the Stalking Horse Purchaser will own all of the outstanding equity of Just Energy Corp., which will be the new parent company of all of the Just Energy Entities including the Company, and the Just Energy Entities will continue their business and operations as a going concern. All currently outstanding shares, options and other equity of Just Energy will be cancelled or redeemed for no consideration and without any vote or other action of the existing shareholders. Key terms of the Stalking Horse Transaction include: the purchase price payable pursuant to the Stalking Horse Transaction is cash in the amount of approximately US$184.9 million, plus up to an additional C$10 million solely in the event that additional amounts are required to make applicable payments pursuant to the Stalking Horse Transaction Agreement; plus a credit bid of approximately US$230 million plus accrued interest of secured claims assigned to the Stalking Horse Purchaser; plus the assumption of Assumed Liabilities, including up to CAD$10 million owing under the Company's first lien credit facility that may remain outstanding under an amended and restated credit agreement. applicable post-filing claims, the Credit Facility Remaining Debt, claims by energy regulators, and certain other liabilities enumerated in the Stalking Horse Transaction Agreement will continue to be liabilities of the Just Energy Entities following consummation of the Stalking Horse Transaction. excluded liabilities and excluded assets of the Just Energy Entities will be discharged from the Just Energy Entities pursuant to the Vesting Order. The consummation of the Stalking Horse Transaction is subject to satisfaction or waiver of a number of conditions precedent set forth in the Stalking Horse Transaction Agreement including, among other things, receipt of all required regulatory approvals, the Court granting the Vesting Order and the recognition of such Vesting Order by the U.S. Court. The outside date for completion of the Stalking Horse Transaction is December 14, 2022, subject to extension in certain circumstances set forth in the Stalking Horse Transaction Agreement. Under the Stalking Horse Transaction, no amounts will be available for distribution to the Just Energy Entities' general unsecured creditors, including the holders of Just Energy's USD $205.9 million term loan and the holders of Just Energy's 7.0% subordinated notes due September 15, 2026, unless expressly classified as "Assumed Liabilities" pursuant to the Stalking Horse Transaction Agreement. Liabilities that will not be retained, including the Term Loan and the Notes, will be transferred to newly formed corporations, along with excluded assets, under the Stalking Horse Transaction Agreement. The Company expects that there will not be any recoveries available from the ResidualCos. Just Energy will be requesting that the Court order that no meeting of the shareholders or other holders of equity claims in the Just Energy Entities is required in respect of the transactions and accordingly, there is no requirement to send any disclosure document related to the transaction to such holders. Implementation of the Stalking Horse Transaction is subject to a condition that Just Energy and the other Just Energy Entities will have ceased to be a reporting issuer under any Canadian or U.S. securities laws, and that no Just Energy Entity will become a reporting issuer under any Canadian or U.S. securities laws as a result of completion of the transaction. In connection with the completion of the Stalking Horse Transaction, the Company intends to: apply for an order from Canadian securities administrators that it will cease to be a reporting issuer under Canadian securities laws immediately prior to the effective date of the transaction; and file to suspend its reporting obligations under U.S. securities laws. Additionally, the Company intends to submit an application to de-list its common shares from trading on the NEX on or before the closing of the Stalking Horse Transaction. The Company's common shares are also quoted on the OTC Pink Sheets. Concurrent with the delisting from the NEX, the Company expects that the common shares will be delisted from OTC Pink Sheets.

07:38 EDT Phillips 66 announces installation of FreeWire EV chargers in Houston - Phillips 66 announced the installation of FreeWire ultrafast electric-vehicle chargers at its flagship fuel station near its headquarters in Houston, marking the debut of ultrafast EV charging at a convenience fuel station in the city. Phillips 66 and FreeWire unveiled plans earlier this year to deploy FreeWire's ultrafast, battery-integrated technology to meet the growing demand from EV drivers for high-speed, on-the-go charging. Phillips 66 will leverage its network of approximately 7,000 Phillips 66, Conoco and 76 branded U.S. sites and other strategic locations. The chargers are the first commissioned FreeWire chargers in Texas.

07:36 EDT Turning Point Brands sees FY22 adjusted EBITDA $96M-$99M - The company also updated its FY22 outlook ahead of its regularly scheduled conference call, which is scheduled for Wednesday, October 26. The company said, "For the full-year 2022, the Company now expects: Zig-Zag Products sales of $186 to $191 million (compared to previous outlook of $193 to $200 million). Stoker's Products sales of $128 to $132 million (compared to previous outlook of $127 to $133 million). Consolidated adjusted EBITDA of $96 to $99 million (compared to previous outlook of $97 to $103 million)."

07:35 EDT Palatin's Vyleesi shows efficacy in published study on sexual desire disorder - Palatin announced the publication of a third-party clinical study with bremelanotide - Vyleesi - in the Journal of Clinical Investigation. Vyleesi is the first and only as-needed treatment approved by the FDA for premenopausal women with HSDD. The findings in the crossover study showed that bremelanotide enhanced sexual brain processing, including a significant increase in sexual desire for up to 24 hours after administration compared with placebo. Increased satiety and decreased food intake with bremelanotide treatment was also noted. This is the first trial to study the effects of melanocortin 4 receptor agonism with bremelanotide on sexual brain processing in women with HSDD. This was an investigator-sponsored study funded by AMAG Pharmaceuticals and the Medical Research Council and National Institute for Health Research of the U.K. Vyleesi is licensed to Fosun Pharma in China and Kwangdong Pharmaceuticals in South Korea.

07:34 EDT NGM Biopharmaceuticals announces results from CATALINA Phase 2 trial of NGM621 - NGM Biopharmaceuticals announced topline efficacy and safety results from its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. NGM621 is a humanized immunoglobulin G1 monoclonal antibody designed to inhibit activity of complement component 3. Over 52 weeks of treatment, NGM621 administered every four weeks and every eight weeks via intravitreal injection demonstrated a reduction in the rate of change in GA lesion area of 6.3% and 6.5%, respectively, compared to sham, which did not reach statistical significance in either arm. NGM621 demonstrated a favorable safety profile, with no evidence of increased choroidal neovascularization conversions and numerically fewer cases of CNV in NGM621-treated patients compared to sham. In addition, there were no drug-related serious adverse events. "We're disappointed that the CATALINA study did not meet its primary endpoint, particularly given the significant unmet medical need of patients impacted by GA," said David Woodhouse, Ph.D., Chief Executive Officer at NGM Bio. "We continue to evaluate various pre-specified secondary endpoints and post-hoc analyses. We expect these additional findings, as well as the absence of treatment-related CNV conversion and the overall clean safety profile NGM621 showed in CATALINA, to provide important information regarding the treatment of patients with GA."

07:32 EDT Turning Point Brands CEO Yavor Efremov resigns, Graham Purdy succeeds - Turning Point Brands announced the appointment of long-tenured company executive Graham Purdy as CEO and board director, effective as of October 16, following Yavor Efremov's resignation as CEO and director. Additionally, David Glazek will transition from non-executive to executive board chairman, effective January 2023. Purdy will lead TPB's strategy, execution, and operations, with a particular focus on growing and maximizing the value of the company's portfolio of iconic and emerging brands. Prior to his appointment as CEO, Purdy served as COO since 2019.

07:32 EDT Summit Midstream announces bolt-on acquisitions in the DJ Basin - Summit Midstream Partners announced that its wholly owned subsidiary, Summit Midstream Holdings, has entered into definitive agreements with Outrigger Energy II LLC to acquire Outrigger DJ Midstream LLC and with Sterling Investment Holdings LLC to acquire, Sterling Energy Investments LLC, Grasslands Energy Marketing LLC and Centennial Water Pipelines LLC, which own natural gas gathering and processing systems, a crude oil gathering system, freshwater rights, and a subsurface freshwater delivery system in the DJ Basin for cash consideration of $305M, subject to customary transaction adjustments. The Outrigger DJ and Sterling DJ consolidated asset portfolio is located in Weld, Morgan, and Logan Counties, Colorado and Cheyenne County, Nebraska. The transactions are expected to close during the fourth quarter of 2022, subject to customary regulatory approvals. The company said, "Given the attractive acquisition multiple of approximately 4.0x projected 2023 EBITDA, we believe these transactions create tremendous equity value for our unitholders while enhancing Summit's overall credit metrics and ability to de-lever the balance sheet over the next several years. The transactions received strong support from our existing commercial bank lenders and bondholders enabling us to finance the acquisitions through the combined $115 million of previously announced divestiture proceeds, borrowings under our credit facility, and an oversubscribed, fully committed, new issuance of $85 million of 8.5% Senior Secured Second Lien Notes due 2026. While we are still several months away from providing formal 2023 guidance, we believe the combination of the previously announced projected 2023 Adjusted EBITDA growth associated with Summit's existing businesses and the $70 million to $80 million of Adjusted EBITDA projected from the Outrigger DJ and Sterling DJ systems next year will result in Summit's consolidated EBITDA exceeding $300 million in 2023 and lowering leverage to approximately 4.25x by year end. Furthermore, if the expected level of 2023 new well connect activity from Summit's current assets and the Outrigger DJ and Sterling DJ systems persist into 2024, we believe we are well positioned to achieve our sub-3.5x leverage target in 2024."

07:29 EDT Laser Photonics says Detroit Diesel implements CleanTech system in facilities - Laser Photonics announced that Detroit Diesel recently completed the implementation of its first CleanTech Laser Cleaning Robot system in its manufacturing facilities.

07:26 EDT New York Mortgage reports book value per share $3.62-$3.66 at Sept. 30 - New York Mortgage Trust announced preliminary estimates of select financial information as of and for the quarter ended September 30, 2022 in light of sustained market volatility. Book value per common share. Book value per common share at September 30, 2022 was estimated to be between $3.62 and $3.66 compared to $4.06 per common share at June 30, 2022. Undepreciated book value per common share. Undepreciated book value per common share at September 30, 2022 was estimated to be between $3.86 and $3.90 compared to $4.24 per common share at June 30, 2022. Company recourse leverage ratio and portfolio recourse leverage ratio. Company recourse leverage ratio was estimated to be 0.5x and portfolio recourse leverage ratio was estimated to be 0.4x as of September 30, 2022. Liquidity position. The Company has maintained a strong liquidity position, with $336 million of available cash and $586 million of unencumbered residential loans, investment securities and mezzanine lending investments as of September 30, 2022. Cash dividend. As previously announced on September 16, 2022, the Company declared a third quarter 2022 common stock cash dividend of $0.10 per share, payable on October 26, 2022 to holders of record as of September 26, 2022. Stock repurchase program. The Company repurchased 5.5 million shares of its common stock at an average repurchase price of $2.62 per share during the quarter ended September 30, 2022.

07:21 EDT Evotec, TIAP expand LAB150 BRIDGE partnership to expand Amgen - Evotec (EVO) and Toronto Innovation Acceleration Partners, or TIAP, announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen (AMGN) as a strategic partner. The expansion goes along with a combined investment of $14M to expedite LAB150 programs towards the formation of new companies. LAB150 was created by Evotec and TIAP in 2017 to accelerate Toronto's academic research into market-ready products. The expanded agreement builds upon existing partnerships between Evotec, TIAP, and Amgen to support the development of disruptive therapeutics by TIAP's member base and draws upon Evotec's industrialized drug discovery platforms. Amgen will provide financial support for chosen LAB150 projects along with mentorship from their drug discovery and development teams. In addition, Amgen Ventures will evaluate LAB150-derived companies for venture investment. These combined efforts will amplify the efficiency and translational potential of academic research to develop Canadian intellectual property, novel therapies, and accelerate commercialization by Canada's next generation of life science companies.

07:18 EDT EyePoint reports inducment grants under NASDAQ listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 42,900 shares of EyePoint Pharmaceuticals common stock to twelve new employees. The stock options were granted on October 14, 2022. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4).

07:17 EDT CTO Realty Growth announces acquisition of property in Virginia for $93.9M - CTO Realty Growth announced it has acquired West Broad Village, a 392,000 square foot mixed-use, grocery-anchored lifestyle property in the Short Pump submarket of Richmond, Virginia for a purchase price of $93.9 million. The purchase price represents a going-in cap rate above the range of the Company's current guidance for initial cash yields. "We're very pleased to be adding to our grocery-anchored asset exposure with our acquisition of West Broad Village, our first Whole Foods and REI-anchored lifestyle property," said John Albright, President and Chief Executive Officer of CTO Realty Growth. "With future leasing opportunities to drive attractive stabilized cash flows, strong supporting demographics, and Richmond's high quality of life, business friendly policies and consistent population growth, West Broad Village represents a terrific opportunity for us to invest in a dominant grocery-anchored lifestyle property with long-term upside."

07:16 EDT Decibel Therapeutics receives FDA clearance of IND for DB-OTO - Decibel Therapeutics (DBTX) announced that it has received clearance from the U.S. Food and Drug Administration, FDA, for its Investigational New Drug, IND, application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is designed to provide durable hearing in individuals born with profound congenital hearing loss due to an otoferlin deficiency. DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals (REGN) and is an adeno-associated virus-based, dual-vector, gene therapy product candidate. DB-OTO uses a proprietary, cell-selective promoter to express the otoferlin transgene in hair cells, with the goal of enabling the ear to transmit sound to the brain and provide hearing. DB-OTO received Orphan Drug and Rare Pediatric Disease designations from the FDA in 2021. In preclinical studies, Decibel observed that delivery of DB-OTO to the inner ear resulted in production of otoferlin protein and durable auditory brainstem responses to sound in a congenitally deaf, rodent otoferlin disease model. Preclinical studies in non-human primates demonstrated that the local delivery procedure for DB-OTO, an intra-cochlear injection using the surgical approach employed by neurotologists and pediatric otolaryngologists during a standard cochlear implantation procedure, resulted in successful distribution and expression of otoferlin protein across the cochlear length. The Phase 1/2 dose escalation clinical trial is designed to evaluate the safety, tolerability and efficacy of DB-OTO in pediatric patients with congenital hearing loss due to an otoferlin deficiency. In addition to safety and tolerability endpoints, established, clinically relevant, objective and behavioral measurements of hearing will be used as efficacy endpoints in the clinical trial. Based on discussions with the FDA during the IND review period, Decibel expects the first two participants in the U.S. portion of the Phase 1/2 trial will be as young as seven years of age and that subsequent participants will include children as young as two years of age and infants younger than two years of age.

07:13 EDT Zentalis appoints Lackner as Chief Translational Officer - Zentalis Pharmaceuticals (ZNTL) announced the appointment of Mark Lackner, PhD, as Chief Translational Officer, Head of Biomarker Strategy. Prior to Zentalis, Dr. Lackner served as Senior Vice President, Head of Biology and Translational Sciences at IDEAYA Biosciences (IDYA), where he led biology efforts contributing to three small molecule development candidates and established a strong translational team that led to the discovery of a novel combination biomarker strategy.

07:10 EDT Lizhi celebrates anniversary with 'Culture Day' live event - LIZHI celebrated its ninth anniversary, commemorating the occasion with a live broadcasting event together with all LIZHI employees around the world. LIZHI also announced the Company's latest mission statement and vision: To be the world's biggest audio platform. Using sound to make people feel closer and live happier.

07:09 EDT Barrick Gold, Pakistan review progress on Reko Diq project - Barrick Gold president and chief executive Mark Bristow says the process of completing the final agreements and legal steps that would enable the development of the Reko Diq project is making steady progress. Once the transaction is completed, Reko Diq, one of the largest undeveloped copper-gold deposits in the world, will be owned 50% by Barrick, 25% by Balochistan province and 25% by major Pakistani state-owned enterprises. With the approval of Pakistan president Dr Arif Alvi, the necessary documents for the Presidential Reference were filed on Saturday with the country's supreme court, a significant process milestone. "Barrick has been built on successful partnerships with our host countries, and these encompass the full range of stakeholders, from governments through suppliers to the communities around our mines," Mark Bristow says.

07:07 EDT Enova doses 1st patient in EDP-323 trial to treat respiratory syncytial virus - Enanta Pharmaceuticals announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus RSV . "This first-in-human study of EDP-323, our selective, direct-acting antiviral specifically targeting the RSV L-protein, is an important milestone for Enanta as we mark the continued expansion of our clinical RSV portfolio. Compelling preclinical data show that EDP-323 potently blocks RSV replication and pathology across all RSV genotypes positioning EDP-323 as a potentially best-in-class potent oral antiviral treatment for RSV," said Scott T. Rottinghaus, M.D., Senior Vice President and Chief Medical Officer of Enanta Pharmaceuticals. "EDP-323 could be used as a monotherapy or in combination with other RSV mechanisms, such as EDP-938, to broaden the addressable patient populations or treatment windows. As we continue to build upon our leadership in the RSV space, we believe having two unique mechanisms to treat the virus could potentially provide additional benefit to patients."

07:06 EDT Ashland launches 2021 ESG report - Ashland has "raised the bar on its business-driven environment, social, and governance, ESG, targets by demonstrating a clear link between its long-range strategic plans and detailed ESG progress," the company said. The report expands on Ashland's February 2021 commitment to develop science-based targets that are aligned with the aim of the Paris Climate Accord. "This ESG report stands alongside quarterly earnings, year-end results and long-term plans as a principal document for charting the evolution of the Ashland transformation," said Guillermo Novo, chair and chief executive officer, Ashland. "We understand and demonstrate at every level how environmental actions, social strategies and public accountability and transparency are vital to business results and the value we deliver to customers, consumers, and the communities in which we live and work. These initiatives reinforce Ashland's recent reset and provide a platform for sustainable innovations that will foster top-line growth in the transition to a low-carbon economy."

07:04 EDT Amryt Pharma receives reimbursement approval from Dutch MoH for myalepta - Amryt announces that the Dutch Ministry of Health, MoH, has approved Myalepta for reimbursement in the Netherlands as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy in adults and children two years of age and above. Myalepta received marketing authorisation from the European Medicines Agency in 2018. Dr Joe Wiley, CEO of Amryt Pharma, commented today: "We are very pleased to report the Dutch reimbursement of Myalepta which will now give patients in the Netherlands suffering from generalized lipodystrophy the opportunity to access Myalepta. This news represents further progress in our efforts to grow the geographic reach of our commercial products in both existing and new territories."

07:04 EDT TD Synnex now formally transitioned TD SYNNEX brand in Europe and Latin America - TD Synnex announced that the company has now formally transitioned to the TD SYNNEX brand in its operations in Europe and Latin America and the Caribbean LAC. The news comes after the merger between Tech Data and SYNNEX Corporation in 2021, which created an industry leader uniquely positioned to serve partners and vendors in over 100 countries with a comprehensive portfolio of products, solutions and service offerings. "This is a special moment of celebration as we launch the TD SYNNEX brand in Europe and LAC," said Rich Hume, CEO, TD SYNNEX. "In this new phase, we will double down on our commitment to delivering higher value to our ecosystem partners through our end-to-end technology portfolio and our comprehensive services offerings, all underpinned by the passion, commitment and deep knowledge of our 22,000+ co-workers around the world."

07:03 EDT BofA added 418K net new checking accounts, 1.3M credit card accounts in Q3 - Comments taken from Q3 earnings conference call presentation slides.

07:03 EDT Zynerba presents data from Phase 2 INSPIRE trial in 22q11.2 deletion syndrome - Zynerba Pharmaceuticals presented a poster at the 2022 National Organization for Rare Disorders, NORD, Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington, D.C. The poster, titled, "An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome," reports data from the first 14-week treatment period that suggests a positive risk-benefit profile for Zygel in improving anxiety-related and behavioral symptoms in children and adolescents with 22q11.2 deletion syndrome. Statistically significant improvements from baseline were seen in the Pediatric Anxiety Rating Scale, the total score and all five subscales of the Anxiety, Depression and Mood Scale and all five subscales of the Aberrant Behavior Checklist - Community. In addition, the majority of patients showed clinically meaningful improvements as demonstrated by the Clinical Global Impression - Improvement. Zygel was shown to be well tolerated, and the safety profile was consistent with previously released data from other Zygel clinical trials. "We are encouraged by the results from our Phase 2 INSPIRE study, where we saw statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, including significant improvement in anxiety as measured by the clinician-rated PARS-R scale," said Armando Anido, Chairman and Chief Executive Officer of Zynerba. "We believe the Phase 2 data suggests the potential of Zygel for the treatment of anxiety and behavioral symptoms in children and adolescents with 22q, and we look forward to discussing the regulatory path forward with the FDA later this half."

06:56 EDT Aecom joint venture awarded water purification contract in San Diego - Aecom's joint venture with W.M. Lyles has been awarded a contract amendment by the Joint Powers Authority to support the East County Advanced Water Purification Program in San Diego, California. The program, which recently broke ground, includes a new water recycling facility, biosolids processing, an advanced water purification facility, and conveyance infrastructure, including pipelines and pumping stations. The joint venture's scope is expected to include final design, construction management, startup, and commissioning and the project is scheduled to be completed in 2026.

06:48 EDT Bank of America reports Q3 FICC trading revenue ex-DVA $2.57B

06:47 EDT BofA grew loans by 12% over last year, says CEO Moynihan - Chairman and CEO Brian Moynihan commented: "We continued to see strong organic client growth across our businesses, with increased client activity helping to drive revenue up by 8%. Our U.S. consumer clients remained resilient with strong, although slower growing, spending levels and still maintained elevated deposit amounts. Across the bank, we grew loans by 12% over the last year as we delivered the financial resources to support our clients. Our team adapted well to our new capital requirements and improved our CET1 ratio by 49 basis points to 11%, above our new regulatory minimums. I am proud of our teammates' efforts to deliver for our clients and shareholders."

06:39 EDT GSK reports FDA approves Menveo in new single-vial presentation - GSK plc announced that the U.S. Food and Drug Administration has approved a new presentation of Menveo for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. "The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation will initially be available to US federal customers, with broader availability anticipated in mid-2023. The original two-vial presentation of Menveo requiring reconstitution, was approved by the FDA in 2010 and remains available for use in individuals from two months to 55 years of age," the company stated.

06:34 EDT Denison Mines recovers uranium bearing solution from Phoenix ISR FFT - Denison Mines announced that it has successfully recovered uranium bearing solution from the Phoenix in-situ recovery, or ISR, Feasibility Field Test underway at the company's 95% owned Wheeler River project. The leaching phase of the FFT commenced in September and preliminary results received to date have demonstrated the successful acidification of the Test Pattern and recovery of uranium through the ISR mining method. Several samples of recovered solution have been collected during the leaching phase and remain subject to full lab assay and analysis, which will generate additional detailed information about the performance of the FFT. Given the highly successful results of the FFT, lixiviant injection has ceased, and operators at the Phoenix FFT site are preparing to transition from the leaching phase of the FFT to the neutralization phase, which is expected to be completed before the end of the year. The final phase of the FFT, which involves management of the recovered solution, is expected to commence in the spring of 2023.

06:31 EDT ESAB acquires Ohio Medical for $127M in cash - ESAB announced that it has acquired Ohio Medical, a global leader in oxygen regulators and central gas systems, from a private investor group for a cash purchase price of $127M. The company also expects an additional cash tax benefit with a net present value of $15M. During the twelve months ended August 31, 2022, Ohio Medical generated over $45M of sales, gross margins above 40%, and adjusted EBITDA margins greater than 20%. The acquisition is expected to be adjusted EPS accretive to ESAB in the first year. The company financed the acquisition using cash on hand and expects its net leverage ratio to be less than 3x at the end of 2022. ESAB will provide additional information during its earnings call on Thursday, November 3.

06:12 EDT Energous partnering with NGK Insulators for IoT wireless power networks - Energous and battery manufacturer NGK Insulators announced a partnership to develop solutions that combine Energous' WattUp technology with NGK's lithium-ion rechargeable EnerCera battery to enable maintenance-free IoT devices such as sensors and tracking devices supporting the growing IoT ecosystem. Headquartered in Nagoya, Japan, NGK developed the lithium-ion rechargeable EnerCera battery which is a new, compact, and thin energy storage device that combines the advantages of capacitors and lithium-ion batteries. This partnership will combine NGK's batteries with Energous' RF-based WattUp technology to deliver over-the-air power to recharge batteries to support maintenance-free IoT applications that do not require battery replacement or power cables.

06:08 EDT Enphase Energy and Creaton expand IQ battery deployments in Germany - Enphase Energy announced that Creaton, one of the leading residential roof manufacturers in Europe, is now exclusively offering Enphase IQ Batteries, following the product launch in Germany last year. Creaton, with offices and manufacturing plants located across Germany, offers a range of products for pitched roof solutions. Creaton began its collaboration with Enphase in 2020 through offering in-roof solar systems powered exclusively by Enphase IQ7 and IQ7+ Microinverters to homeowners across Germany. Creaton is now able to integrate battery installations into solar roofing projects to provide an end-to-end roofing and home energy management experience.

06:05 EDT Largo Inc. reports Q3 V2O5 production 2,906 tons vs. 3,260 a year ago - Largo Inc. reported Q3 V2O5 production of 2,906 tons vs. 3,260 tons in Q3 2021; lower quarterly production was due to a planned kiln and cooler refractory refurbishment and a change of mining contractor, but was in line with the company's revised production guidance. Reports Q3 record high purity V2O5 equivalent production of 962 tons, or 33% of the company's Q3 production. Reports Q3 V2O5 equivalent sales of 2,796 tons vs. 2,685 tons sold in Q3 2021; completed first high purity V2O3 sale in Europe in Q3. Average benchmark price per lb of V2O5 in Europe of $8.23, a 12% decrease from the average of $9.40 in Q3 2021; high purity vanadium demand has increased following ongoing recovery from 2020 COVID-19 impacts. Advanced construction of its ilmenite concentration plant; expects commissioning completed in Q2 2023. CEO Paulo Misk stated: "Production of V2O5 in Q3 2022 was impacted by a refractory refurbishment and a mining contractor transition, while V2O5 equivalent sales were affected by shipping delays and lower spot demand. However, despite experiencing production impacts, the Company produced 962 tonnes of high purity material in the quarter to meet increased demand from this sector. The company remains on track to meet its 2022 production and sales guidance range of 11,000 to 12,000 tons."

06:02 EDT Biodesix awarded U.S. Federal Supply Schedule contract - Biodesix announced the award of a U.S. Federal Supply Schedule contract which includes the Veterans Health Administration providing care for U.S. Veterans and Military Health System providing care for active-duty service members and their families. The contract covers the company's entire lung diagnostic portfolio: Nodify XL2, Nodify CDT, VeriStrat, GeneStrat ddPCR, and GeneStrat NGS testing. The U.S. Department of Veterans Affairs is the largest integrated health care system in the United States and provides care at 1,298 health care facilities, including 171 VA Medical Centers and 1,113 outpatient sites of care of varying complexity to over 9 million veterans enrolled in the VA health care program.

05:43 EDT Globant announces multi-year agreement with Globant - FIFA has struck a multi-year agreement with Globant to supercharge the growth of the FIFA+ streaming platform and support football's flagship events, starting with the FIFA World Cup Qatar 2022. Globant will be the Global Platform Supporter of FIFA+, the game-changing digital destination launched earlier this year. As part of its responsibilities, Globant - which has 25,900 employees and a presence in 20 countries - will create new features and connected experiences for FIFA+ users while supporting the distribution of the platform. In addition, the company will be a Regional Supporter of this year's FIFA World Cup in North America and Europe, as well as a Sponsor of the FIFA Women's World Cup Australia & New Zealand 2023. Globant will also be a FIFAe Series Global Sponsor in 2023, 2024 and 2025, and a worldwide Tournament Supporter of the FIFA U-17 Women's World Cup 2024, FIFA U-20 Women's World Cup 2024, FIFA U-17 World Cup 2025 and FIFA U-20 World Cup 2025.

05:28 EDT Nokia selected as major supplier by Reliance Jio for 5G ran - Nokia announced that it has been selected as a major supplier by Reliance Jio to supply 5G Radio Access Network, or RAN, equipment from its comprehensive AirScale portfolio countrywide in a multi-year deal. Reliance Jio is India's number one mobile operator and has one of the largest RAN footprints in the world. Under the contract, Nokia will supply equipment from its AirScale portfolio, including base stations, high-capacity 5G Massive MIMO antennas, and Remote Radio Heads, or RRH, to support different spectrum bands, and self-organizing network software. Reliance Jio plans to deploy a 5G standalone network which will interwork with its 4G network. The network will enable Reliance Jio to deliver advanced 5G services such as massive machine-to-machine communications, network slicing, and ultra-low-latency.

05:22 EDT Nokia announces Generation 6 broadband platform - Nokia has announced the world's first Generation 6 broadband platform, designed for a 'fiber-for-everything' world where fiber broadband networks evolve to become a single infrastructure for all services. The new Lightspan MF-14 platform extends the upper end of Nokia's fiber broadband portfolio. The new platform will be premiered at the Network X event in Amsterdam.

05:16 EDT 36Kr Holdings Enterprise Service Review Platform enters partnership with Lenovo - 36Kr Holdings announced that its Enterprise Service Review Platform has entered into strategic cooperation with Lenovo. 36Kr will provide in-depth marketing services designed to empower Lenovo's business unit targeting small- and medium-sized businesses with customer acquisition solutions, as well as improve its brand influence. Under the cooperation, 36Kr will provide a broad array of value-added services, including precise customer acquisition, brand management and interactive marketing, among others. Leveraging its advanced big data analytics, 36Kr Enterprise Service Review Platform will identify effective marketing qualified leads for Lenovo SMB. At the same time, the platform will extend Lenovo's reach among potential customers through diverse marketing campaigns, such as live streaming events, specialized forums and evaluation reports. Notably, 36Kr and Lenovo jointly created a content channel targeting "specialized, refined, differentiated and innovative" enterprises to enhance Lenovo's brand influence and empower small- and medium-sized enterprises to expand their businesses. The Lenovo-sponsored channel was launched on 36Kr's official website in August this year.